Dang Beijing, Liang Lixin, Li Zhijun, Luo Junli, Zhong Shangwei
The Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang 421009, China.
Biology (Basel). 2025 May 14;14(5):544. doi: 10.3390/biology14050544.
Prostate cancer is among the most frequently diagnosed and deadly cancers among men in the Western world. It is typically classified as an immune "cold" tumor due to its sparse immune cell presence and limited immunogenic response. Recent research has revealed the significant role of immune cells, especially CD8 T cells, in both prostate cancer progression and treatment efficacy. This review integrates recent findings to provide a comprehensive overview of the current understanding of CD8 T cell dynamics in prostate cancer and discusses emerging strategies to improve treatment outcomes. The ongoing exploration of new molecular targets and the development of innovative immunotherapeutic approaches hold promise for more effective management of prostate cancer, particularly in the context of advanced and resistant forms of the disease.
前列腺癌是西方世界男性中最常被诊断出且致命的癌症之一。由于其免疫细胞数量稀少且免疫原性反应有限，它通常被归类为免疫“冷”肿瘤。最近的研究揭示了免疫细胞，尤其是CD8 T细胞，在前列腺癌进展和治疗效果中的重要作用。本综述整合了近期的研究结果，全面概述了目前对前列腺癌中CD8 T细胞动态的理解，并讨论了改善治疗结果的新兴策略。对新分子靶点的持续探索和创新免疫治疗方法的开发，有望更有效地管理前列腺癌，特别是在该疾病的晚期和耐药形式的背景下。
